From Kernel to Clinic: A Perspective on Upcycled Wheat-Milling Co-Products as a Functional “Altograno” Pasta for Cardiometabolic Health

Conventional milling separates the wheat germ and bran from the endosperm to obtain white semolina; although these fractions retain recognized nutritional value, a substantial share is still diverted to feed and other comparatively low-value uses rather than into food for direct human consumption. In this Perspective we ask whether recovering a larger share of these fractions—through a controlled industrial sequence of selection, de-oiling and physical fractionation—can be turned into a functional ingredient, commercialized as “altograno”, that improves the health profile of an ordinary pasta without compromising palatability or shelf stability. To address this objective we proceed in a fixed analytical sequence: what the product is and what a habitual portion actually delivers; a nutrient-by-nutrient appraisal graded by level of evidence; the biological mechanisms from the intestinal lumen to the hepatocyte; and only then the clinical endpoint. The evidence base integrates two complementary studies of one product line from the Casillo Next Gen Food chain: a full nutritional, microbiological and gastrointestinal characterization in healthy volunteers, and a double-blind randomized controlled trial with in vitro hepatocyte evidence in patients with metabolic syndrome (MetS), with and without major psychiatric disorders (MPDs). Because the clinically tested product (67% semolina, 27% de-oiled wheat germ, 6% microencapsulated wheat-germ oil) shares the same nominal formulation as the germ-plus-oil pasta (EP3) of the characterization study—although the measured nutritional values reported in the two papers differ, so the two products cannot be regarded as analytically identical—the two datasets can be read together, with due caution, across kernel processing, composition, hepatocellular mechanism and gut-microbiota switching to a clinical endpoint: a ~13.5% fall in non-HDL cholesterol, roughly 2.5-fold greater than with conventional pasta, with no statistically significant interaction with the polygenic risk score detected, and paralleled by normalized hepatocyte lipid loading in vitro. We argue that de-oiling is best understood as a deliberate technological optimization—trading a portion of labile lipids for stability and standardization while recovering the bioactive oil for protected re-addition—and that this evidence, while still preliminary on several fronts, supports dedicated, mechanistically instrumented clinical development of upcycled-kernel staples rather than establishing these products as proven therapeutic tools.